Epizyme, Inc. (EPZM) Analysts See $-0.53 EPS

July 12, 2018 - By Kristen Paramore

Epizyme, Inc. (NASDAQ:EPZM) LogoInvestors sentiment increased to 1.5 in Q1 2018. Its up 0.29, from 1.21 in 2017Q4. It increased, as 13 investors sold Epizyme, Inc. shares while 25 reduced holdings. 22 funds opened positions while 35 raised stakes. 57.44 million shares or 0.90% more from 56.93 million shares in 2017Q4 were reported.
Moreover, Bank Of America Corporation De has 0% invested in Epizyme, Inc. (NASDAQ:EPZM). Tiaa Cref Investment Mngmt Limited Liability Com has 110,943 shares. Ubs Asset Mngmt Americas has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Northern Tru Corporation stated it has 0% in Epizyme, Inc. (NASDAQ:EPZM). Rhumbline Advisers holds 48,210 shares. Royal National Bank Of Canada accumulated 880 shares. Bailard Inc, California-based fund reported 25,000 shares. Sio Cap Management Ltd Liability Corp owns 72,826 shares. Fred Alger Mgmt Inc, New York-based fund reported 20,000 shares. Rhenman & Prtn Asset Mgmt Ab accumulated 181,291 shares. Meeder Asset Mgmt owns 73 shares. Franklin Resource Inc holds 0.01% or 960,200 shares. Tekla Limited Com accumulated 485,325 shares or 0.34% of the stock. 11,090 are owned by Ameriprise. Macquarie Group Inc Limited invested in 242,121 shares.

Since February 5, 2018, it had 0 buys, and 1 sale for $1.20 million activity.

Analysts expect Epizyme, Inc. (NASDAQ:EPZM) to report $-0.53 EPS on August, 3.They anticipate $0.05 EPS change or 10.42 % from last quarter’s $-0.48 EPS. After having $-0.49 EPS previously, Epizyme, Inc.’s analysts see 8.16 % EPS growth. The stock increased 1.50% or $0.2 during the last trading session, reaching $13.5. About 59,510 shares traded. Epizyme, Inc. (NASDAQ:EPZM) has risen 14.24% since July 12, 2017 and is uptrending. It has outperformed by 1.67% the S&P500.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Among 6 analysts covering Epizyme (NASDAQ:EPZM), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Epizyme had 9 analyst reports since January 24, 2018 according to SRatingsIntel. H.C. Wainwright maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Wednesday, March 14. H.C. Wainwright has “Buy” rating and $25.0 target. SunTrust maintained Epizyme, Inc. (NASDAQ:EPZM) on Monday, April 23 with “Buy” rating. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Market Perform” rating given on Tuesday, July 3 by Leerink Swann. As per Tuesday, April 24, the company rating was maintained by Roth Capital. The company was maintained on Wednesday, March 14 by Leerink Swann. The firm has “Buy” rating by Jefferies given on Wednesday, January 24. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Outperform” rating given on Tuesday, April 24 by Wedbush. The firm has “Buy” rating by Roth Capital given on Thursday, February 1. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Buy” rating by Leerink Swann on Tuesday, April 24.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $938.09 million. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Higher; Acuity Brands Beats Q3 Expectations” on July 03, 2018, also Schaeffersresearch.com with their article: “eBay Counters Amazon; Acuity Brands Stock Jumps After Earnings” published on July 03, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on July 03, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Streetinsider.com and their article: “Epizyme (EPZM) PT Raised to $27 at Oppenheimer” published on July 09, 2018 as well as Seekingalpha.com‘s news article titled: “Epizyme’s tazemetostat shows positive effect in mid-stage lymphoma study” with publication date: June 15, 2018.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: